title: Therapy for acute pancreatitis with platelet-activating factor receptor antagonists.
abstract: Acute pancreatitis (AP) causes release of platelet-activating factor (PAF), which induces systemic effects that contribute to circulatory disturbances and multiple organ failure. PAF is a cell surface secretion of bioactive lipid, which could produce physiological and pathological effects by binding to its cell surface receptor called platelet-activating factor receptor (PAF-R). Studies showed that PAF participate in the occurrence and development of AP and administration of platelet-activating factor receptor antagonists (PAF-RAs) could significantly reduce local and systemic events after AP. PAF has also been implicated as a key mediator in the progression of severe AP, which can lead to complications and unacceptably high mortality rates. Several classes of compounds show significant PAF-RAs, and significant local and systemic effects on reducing inflammatory changes. As a preventive treatment, PAF-RA could block a series of PAF-mediated inflammatory injury and thus improve the prognosis of AP. This review introduces the important role of PAF-RA in the treatment of AP.
authors: Department of Gastroenterology, Pancreas Center of Affiliated Hospital of Medical College of Chinese People's Armed Police Forces, Tianjin 300162, China.
authors: Chong
authors: C
authors: Chen
authors: Shi-Hai
authors: SH
authors: Xia
authors: Hong
authors: H
authors: Chen
authors: Xiao-Hong
authors: XH
authors: Li
mesh_terms: D000208:Acute Disease; D000818:Animals; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001381:Azepines / Q000627:therapeutic use; D046934:Ginkgolides / Q000627:therapeutic use; D006801:Humans; D007093:Imidazoles / Q000627:therapeutic use; D007783:Lactones / Q000627:therapeutic use; D007930:Leucine / Q000031:analogs & derivatives / Q000627:therapeutic use; D010195:Pancreatitis / Q000188:drug therapy* / Q000378:metabolism; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D010980:Platelet Membrane Glycoproteins / Q000037:antagonists & inhibitors* / Q000378:metabolism; D011726:Pyridinium Compounds / Q000627:therapeutic use; D043562:Receptors, G-Protein-Coupled / Q000037:antagonists & inhibitors* / Q000378:metabolism; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use
chemical_list: D000893:Anti-Inflammatory Agents; D001381:Azepines; D046934:Ginkgolides; D007093:Imidazoles; D007783:Lactones; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D011726:Pyridinium Compounds; D043562:Receptors, G-Protein-Coupled; D044005:Tetrahydroisoquinolines; D014230:Triazoles; C039351:platelet activating factor receptor; C063964:bepafant; C045856:ginkgolide B; D007930:Leucine; C103289:lexipafant; C067430:TCV 309